Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
Clinical trial NCT05282433 · UNKNOWN
Trial details
- NCT number
- NCT05282433
- Sponsor
- Zhongnan Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-16
- Primary completion
- 2023-12-31
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.